Despite trastuzumab being a game-changing treatment for HER2-positive breast cancers over the past two decades, its success has come with key gaps in the understanding of how, exactly, it works.
Nov 15, 2019
0
7
Radioactive antibodies that target cancer cells are used for medical diagnostics with PET imaging or for targeted radioimmunotherapy. Researchers from the University of Zurich have created a new method for radiolabelling ...
Apr 24, 2019
0
1
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.
Mar 14, 2019
0
40
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018.1
Dec 5, 2018
0
5
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018.
Dec 5, 2018
0
0
Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, ...
Oct 22, 2018
0
0
Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from ...
Apr 10, 2018
0
24
Breast cancer patients who started taking one of two well-known heart medications at the same time they initiated trastuzumab—a targeted cancer therapy that has been linked to heart damage—received no benefit in terms ...
Mar 12, 2018
0
5
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...
Dec 6, 2017
0
1
Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to ...
Dec 1, 2016
0
4
